Brought to you by 
PharmaEngine gets exclusive Asia-Pacific rights to Nanobiotix’s NBTXR3; Collaboration Terminated
16 Nov 2021
Executive Summary
Nanobiotix SA (nanomedicine for cancer drug development) has granted PharmaEngine Inc. (treatments for cancer and Asia-prevalent diseases) exclusive rights to develop and sell its Phase I radiotherapy adjunct NBTXR3 in the Asia-Pacific region, including Australia, China, India, Japan, Korea, and Taiwan.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Nanotechnology, Chips, etc.
- Immuno-Oncology
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
PharmaEngine gets exclusive Asia-Pacific rights to Nanobiotix’s NBTXR3; Collaboration Terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice